Eton Pharmaceuticals, Inc.

NASDAQ:ETON

Biotechnology

Healthcare
$61.99 -1.39%

-$0.46 today

Market cap
$1.79B
Beta
0.89
P/E (TTM)
-597.6
EPS (TTM)
-$0.05
52W Low $13.09High $35.66

Volume 0.48M

Average 0.43M

ETON Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Eton Pharmaceuticals, Inc.NASDAQ: ETON

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows in line with its trailing trend

Q1 FY2026 weighted avg shares of 27.29M shares rose 1.5% year over year, behind the +3.1% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 1.4% from the prior quarter. Over 3 fiscal years it compounded at +2.3% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +1.5% toward the trailing-twelve-month pace of +3.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
27.29M+1.4% QoQ
Last fiscal yearDec 2025
26.91M+3.9% YoY
LTMMar 2026
26.99M+3.1% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.5%——
1 year+3.9%——
3-year CAGR+2.3%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
26.91M USD
Year-over-year change
+3.9%
4-year CAGR
+1.6%

Weighted Avg Shares vs competitors

How ETON compares with its peers on the latest reported figures

  • ETON's LTM Mar 2026 weighted avg shares of 26.99M shares is the lowest of the 10 companies compared; the peer median is 78.18M shares.
  • Its year-over-year change of +3.1% is the 9th highest of 10, against a peer median of +6.8%.
  • Over three fiscal years its annual growth of +2.3% compares with a peer median of +12.1%.
ETON Competitors Peer median
Weighted Avg Shares for ETON and competitors
Company Period LTM YoY 3-year CAGR
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026372.59M +6.8%+29.9%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026164.62M +3.4%+4.1%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 202699.68M +6.6%+12.1%
TVTXTravere Therapeutics, Inc.LTM Sep 202692.57M +5.9%+11.8%
LRMRLarimar Therapeutics, Inc.LTM Mar 202678.18M +22.5%+41.5%
PHARPharming Group N.V.LTM Mar 202667.56M -5.0%-4.8%
ZVRAZevra Therapeutics, Inc.LTM Mar 202656.11M +13.7%+17.1%
DMACDiaMedica Therapeutics Inc.LTM Mar 202648.34M +16.1%+21.1%
FENCFennec Pharmaceuticals Inc.LTM Mar 202630.27M +10.4%+2.8%
ETONEton Pharmaceuticals, Inc.LTM Mar 202626.99M +3.1%+2.3%
Peer median (excluding ETON) 78.18M+6.8%+12.1%

Competitors are the stored peer set for ETON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue21.83M21.25M31.64M39.01M79.95M
Cost of Revenue2.62M6.93M10.58M15.6M37.21M
Gross Profit19.21M14.32M21.06M23.41M42.74M
Gross Margin88.0%67.4%66.6%60.0%53.5%
Research & Development6.24M4M3.32M3.26M7.77M
Selling, General & Admin14.47M18.58M18.93M22.75M35.82M
Operating Expenses20.7M22.58M22.25M26.01M42.67M
Depreciation & Amortization462K1.77M901K1.15M4.04M
EBITDA(1.49M)(7.25M)212K(657K)4.27M
EBITDA Margin-6.8%-34.1%0.7%-1.7%5.3%
Operating Income(1.5M)(8.26M)(1.19M)(2.6M)72K
Operating Margin-6.8%-38.9%-3.8%-6.7%0.1%
Interest Income00000
Interest Expense1.04M955K1.06M2.01M4.78M
Other Income / Expenses(460K)(761K)503K(1.21M)(4.63M)
Income Before Tax(1.96M)(9.02M)(689K)(3.81M)(4.56M)
Pre-Tax Margin-9.0%-42.4%-2.2%-9.8%-5.7%
Income Tax Expense00247K15K43K
Net Income(1.96M)(9.02M)(936K)(3.82M)(4.6M)
Net Margin-9.0%-42.4%-3.0%-9.8%-5.8%
EPS (Basic)(0.08)(0.36)(0.04)(0.15)(0.17)
EPS (Diluted)(0.08)(0.36)(0.04)(0.15)(0.17)
Weighted Avg Shares25.21M25.15M25.65M25.9M26.91M
Weighted Avg Shares (Diluted)25.21M25.15M25.65M25.9M26.91M

Eton Pharmaceuticals, Inc.

NASDAQ:ETON

Intrinsic Alpha fair value

Locked

Current Price

$61.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.